Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is an open phase II study evaluating the efficacy and safety of the non pegylated
liposomal doxorubicin (Myocet®), trastuzumab (Herceptin®), and docetaxel (Taxotere®)
combination as first-line treatment of patients with metastatic HER2/neu positive breast
cancer.